The global clinical trial supplies market is anticipated to reach USD 8.18 billion in 2030 from USD 5.34 billion in 2025, with a significant CAGR of 8.9%. The major factors contributing to the growth of the clinical trial supplies market include growth in pharmaceutical, biotechnology, and medical device clinical trials globally, rising demand for personalized medicine and cell & gene therapy trials and Growth in decentralized and virtual trials.
Based on services, the clinical trial supplies market is segmented into logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services. Logistics & distribution segment dominated the market in 2024. The segment dominated the market owing to increasing globalization of clinical trials, requiring complex supply chain management across multiple regions. The rise in temperature-sensitive investigational products, such as biologics, cell and gene therapies, and vaccines, has further driven demand for specialized cold chain logistics solutions, including cryogenic storage and ultra-low freezers.
The market is segmented by phases into phase I, Phase II, Phase III, Phase IV and Phase BA/BE. Phase III dominated the market in 2024. Phase III trials involve thousands of patients across multiple locations, increasing the demand for investigational drugs, comparator drugs, and ancillary supplies. The high costs and complexity of these trials drive the need for efficient logistics, cold chain management, and regulatory compliance to ensure the timely delivery of trial materials
The clinical trial supplies market is segmented by type into biologics, small molecules and medical device. In 2024, small molecules dominated the market owing to their widespread use in drug development and high success rates in clinical trials. Small molecule drugs remain the primary focus for pharmaceutical companies due to their well-established manufacturing processes, ease of oral administration, and cost-effectiveness compared to biologics.
The clinical trial supplies market is further segmented by end users into pharmaceutical and biotechnology companies, CROs and CDMOs, and other end users. The pharmaceutical and biotechnology companies dominated the end users segment owing to their extensive involvement in drug development and the increasing number of clinical trials. These companies drive the demand for investigational drugs, comparator drugs, and ancillary supplies across all trial phases, particularly in Phase III, which requires large-scale patient recruitment and complex supply chain management.
North America dominated the clinical trial supplies market in 2024 due to its well-established pharmaceutical and biotechnology industries, which drive high R&D investments in drug development. The region benefits from a strong regulatory framework, including the FDA’s streamlined approval processes and initiatives supporting decentralized and adaptive trials. Additionally, the presence of leading contract research organizations (CROs) and supply chain service providers enhances efficiency in trial logistics. The growing adoption of direct-to-patient (DTP) drug delivery models, coupled with advancements in cold chain logistics and digital tracking technologies, further strengthened North America’s leadership in the market. Moreover, the increasing number of clinical trials, particularly in oncology and rare diseases, fueled the demand for specialized supplies, reinforcing the region’s dominant position.
US dominated the North America’s clinical trial supplies market. US is benefited from a well-developed logistics and distribution network, supporting complex supply chain needs, particularly for temperature-sensitive biologics. Strong patient recruitment and engagement strategies, including digital platforms and home healthcare services, further bolstered clinical trial activity. Strategic collaborations and mergers between pharmaceutical companies, technology providers, and logistics firms enhanced supply chain innovation, solidifying North America’s leadership in the clinical trial supplies market.
The prominent players operating in the clinical trial supplies market are Thermo Fisher Scientific Inc. (US), Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), and Sharp Services LLC (US), among others.
